Ritlecitinib

Last updated on: 23.04.2025

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Ritlecitinib is a JAK inhibitor and selectively inhibits Janus kinase 3 (JAK3) and tyrosine kinase. Approved on the market in Germany since November 2023. The European Commission has approved ritlecitinib (^Litfulo®) for the treatment of severe alopecia areata in adults and adolescents aged 12 and over. However, German health insurance companies do not cover the costs of this approved preparation: Section 34 SGB V excludes the assumption of costs for drugs to improve hair growth.

Dosage and method of useThis section has been translated automatically.

1 hard capsule per day. Check platelets and lymphocytes before starting therapy and after 4 weeks.

Discontinue therapy if the absolute lymphocyte count is less than 0.5 × ^103/mm3, discontinue if the platelet count is less than 50 × ^103/mm3

Discontinue therapy in case of infections.

LiteratureThis section has been translated automatically.

Last updated on: 23.04.2025